Skip to main content
 
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
02/07/19
Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
- Focusing resources on clinical readouts from late-stage microbiome programs for ulcerative colitis, C. difficile infection and planned immuno-oncology study - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 7, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced certain corporate changes to focus resources on its highest priority, clinical-stage microbiome therapeutic candidates. “We believe that microbiome therapeut... 
01/15/19
Seres Therapeutics Announces Chief Executive Officer Transition
- Eric Shaff, previously Chief Operating and Financial Officer, appointed President and Chief Executive Officer - - Roger J. Pomerantz, M.D., to continue to serve as Chairman - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 15, 2019-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Eric D. Shaff as President and Chief Executive Officer. Mr. Shaff, who is currently Chief Operating and Financial Officer, succeeds Roge... 
01/03/19
Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
– Recent FDA correspondence indicates this SER-287 Phase 2B study may support Biologics License Application (BLA) – – Company has received $40 million in milestone payments with Phase 2B study start – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 i... 
EventsMore
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$6.00
0.00 (0.00%)
02/19/19 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.